Nasdaq bioc

(NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the  BIOC 0.26 0.02 (6.96%). NASDAQUpdated Mar 19, 2020 11:36 AM. 38,901. Watchers. Watch. Filter by: Real-Time. 0 New Post. 0 New Post  BIOC | Complete Biocept Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the Large independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO, Feb. 10, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable BIOC | Complete Biocept Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Income Statement for Biocept, Inc. (BIOC) - view income statements, balance sheet, cash flow, and key financial ratios for Biocept, Inc. and all the companies you research at NASDAQ.com

Biocept (BIOC) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.

Find the latest historical data for Biocept, Inc. Common Stock (BIOC) at Nasdaq.com. Social media updates, opinions, and reactions on Biocept, Inc. (BIOC) aggregated in real time from around the web on NASDAQ.com Find the latest news headlines from Biocept, Inc. Common Stock (BIOC) at Nasdaq.com. Biocept Inc (NASDAQ:BIOC) issued its quarterly earnings results on Wednesday, November, 13th. The medical research company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.02. The medical research company had revenue of $1.53 million for the quarter. BIOC | Complete Biocept Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the Large independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO, Feb. 10, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable

9 Mar 2020 (NASDAQ:BIOC) marked $0.48 per share versus a previous $0.51 closing price. With having a -5.08% loss, an insight into the fundamental 

Researching Biocept (NASDAQ:BIOC) stock? View BIOC's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at  5 Mar 2020 Biocept (BIOC -16.8%) slumps on a 4x surge in volume in reaction to its at-the- market sale of 16M common shares at $0.41 per share (closing  Eye-Catching Stock:: Biocept, Inc., (NASDAQ: BIOC). By. NNF Team. -. March 19, 2020. 0. 21. EPS growth is an important number as it gives a suggestion of the  Bioclinica Inc0.565. NASDAQ:BIOC (3/4/20, 11:00 AM)0.16 (38.48%). After market: 0.59 0.03 (4.42%). Chartmill TA Rating. Chartmill Setup Rating. Sector 

Find the latest historical data for Biocept, Inc. Common Stock (BIOC) at Nasdaq.com.

BIOC's NASDAQ Last Sale (NLS) "Last Sale" is the price at which a stock last traded during regular market hours. NLS Volume "Volume" is the number of shares of the stock traded on the listing exchange during regular trading hours. Previous Close Today's High / Low 52 Week High / Low

BIOC 0.26 0.02 (6.96%). NASDAQUpdated Mar 19, 2020 11:36 AM. 38,901. Watchers. Watch. Filter by: Real-Time. 0 New Post. 0 New Post 

Biocept Inc (NASDAQ:BIOC) issued its quarterly earnings results on Wednesday, November, 13th. The medical research company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.02. The medical research company had revenue of $1.53 million for the quarter. BIOC | Complete Biocept Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the Large independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO, Feb. 10, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable BIOC | Complete Biocept Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the